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(52 strains, 49%), foLLowed by C. pampsilosis (26%) 
and C. slabmta (13%). A total of 55 (53%) of 104 
adult patients had received adequate antifunga[ 
treatment, of whom 43 (78%) were treated with 
fluconazoLe and eight (15%) with micafungin; on 
the other hand, 33 adults received no antifunga[ 
agent. In addition, 16 (15%)patients were treated 
with Low dosages of fluconazoLe. The overaLL mor- 
tality was 45%. MuLtivariate analysis indicated 
that prolonged hospital stay (P = 0.02; OR 2.95; CI 
1.14-7.62), central venous catheter-reLated infec- 
tion (P = 0.007; OR 3.40; CI 1.39-8.29) and inade- 
quate of antifunga[ treatment (P=0.03; OR 2.76; 
CI 1.09-6.99) were associated with candidemia- 
related death. The risk of death was similar in 
patients infected by C. albicans and those infected 
by non-aLbicans Candida spp. 
Conclusions: Candidemia is associated with a high 
mortality rate among criticaLLy iLL patients. In- 
creased awareness of risk factors and cLearLy de- 
fined infection control policies are needed to bet- 
ter address the problem of nosocomia[ Candida 
infections. 
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Introduction: Data on the use of caspofungin in 
combination with other systemic antifunga[ drugs 
for pediatric patients are scanty. 
Methods: A prospective study was performed from 
November 2002 to November 2005 to investigate 
the safety and efficacy of caspofungin-based com- 
bination therapy in children and adolescents. 
Results: Sixty-six patients were recruited with a 
median age at diagnosis of 11.3 years; most of 
them were affected by an underlying malignant 
disease. Twenty-one (32%) patients developed an 
invasive funga[ infection (IFI) after hematopoietic 
stem ceLL transplantation, 22 after primary diag- 
nosis, and 23 after relapse. Severe neutropenia 
was present in 52 (79%) patients. The mycoses 
were classified as possible in 17 (26%), probable 
in 20 (30%) and documented in 29 (44%) patients, 
respectively. A favorable response to antifunga[ 
therapy was obtained in 37 patients (56%) and the 
probability of 100-day survival was 72%. OveraLL, 
the combination therapy was weLL tolerated. After 
a median foLLow-up of 1.2 years, 31 patients were 
alive (47%). The probability of overaLL survival LOS) 
was significantly different for mycosis diagnosed 
after relapse, 20.9%, after HSCT, 32.4%, and after 
primary diagnosis, 48%, p 0.007. In a multivariate 
analysis, underlying disease status was the factor 
associated with favorable response, whilst factors 
associated with 100-day survival were the duration 
of therapy with caspofungin and the achievement 
of a favorable response; and those associated with 
OS were the occurrence of IFI after primary diag- 
nosis, use of surgery, and the achievement of a 
favorable response. 
Conclusion: This study showed that caspofungin- 
based combination antifunga[ therapy is an effica- 
cious therapeutic option for pediatric patients with 
invasive mycoses. These data need to be confirmed 
by prospective controLLed studies. 
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Background: RSV infection might be associated 
with high morbidity and mortality among immuno- 
compromised patients (pts). LittLe is known about 
the outcome of this infection in pts with Leukemia. 
Objectives: To evaluate the impact of antivi- 
ra[ therapy for RSV infection in patients with 
Leukemia. 
Materials & Methods: We reviewed the records of 
such pts seen at our institution between Oct 1999 
and Dec 2004 to determine the cLinicaL characteris- 
tics, risk factors, and outcome in Leukemia pts with 
RSV infection. 
